Sera Prognostics Adds Myriad Genetics Veteran Mark Capone to Board
Event summary
- Mark Capone, former CEO of Myriad Genetics, joins Sera Prognostics' board effective July 1, 2026.
- Capone brings 40 years of healthcare leadership experience in diagnostics and life sciences.
- Sera aims to leverage his expertise in commercializing complex diagnostic products.
- PreTRM Test remains the company's sole revenue source.
The big picture
Sera Prognostics is strengthening its governance with seasoned diagnostics executives as it seeks to expand market penetration for its preterm birth prediction test. The appointment comes amid persistent challenges in the maternal health sector, where preterm births continue to represent significant clinical and economic burdens. Capone's track record at Myriad suggests Sera may prioritize commercial scaling over near-term R&D expansion.
What we're watching
- Commercial Execution
- How Capone's experience will accelerate PreTRM Test adoption.
- Reimbursement Dynamics
- Whether Sera can navigate payer environments more effectively under new leadership.
- Product Diversification
- The pace at which Sera introduces new diagnostic tests beyond PreTRM.